Join Growin Stock Community!

Cingulate inc.CINGW.US Overview

US StockHealthcare
(No presentation for CINGW)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

CINGW AI Insights

CINGW Overall Performance

CINGW AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

CINGW Recent Performance

19.69%

Cingulate inc.

0.05%

Avg of Sector

-0.31%

S&P500

CINGW PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

CINGW Key Information

CINGW Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

CINGW Profile

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of central nervous system and neurobiological disorders. The company's lead product candidates are CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of attention deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas with an additional location in Morristown, New Jersey.

Price of CINGW

CINGW FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

CINGW Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.27
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
99.98%
3-Year Revenue Growth
-%
3-Year Profit Growth
21.60%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.27
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
-
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
100.00%
Profit Growth (YoY)
99.98%
3-Year Revenue Growth
-%
3-Year Profit Growth
21.60%

  • When is CINGW's latest earnings report released?

    The most recent financial report for Cingulate inc. (CINGW) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating CINGW's short-term business performance and financial health. For the latest updates on CINGW's earnings releases, visit this page regularly.

  • How much cash does CINGW have?

    At the end of the period, Cingulate inc. (CINGW) held Total Cash and Cash Equivalents of 6.12M, accounting for 0.58 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is CINGW's EPS continuing to grow?

    According to the past four quarterly reports, Cingulate inc. (CINGW)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -1.35. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of CINGW?

    Cingulate inc. (CINGW)'s Free Cash Flow (FCF) for the period is -4.24M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 13.4% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of CINGW?

    The latest valuation data shows Cingulate inc. (CINGW) has a Price-To-Earnings (PE) ratio of -0 and a Price/Earnings-To-Growth (PEG) ratio of -0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.